PamGene technology involved in four posters at AACR Meeting in Chicago
At the AACR Annual Meeting from March 31 April 4 2012 in Chicago the best and latest findings in all major areas of cancer research were presented in about 5820 abstracts. The theme of the AACR Annual Meeting 2012, Accelerating Science: Concept to Clinic, reflects this amazing progress and emphasizes the synergy between basic, clinical, and translational research that will continue to lead to effective cancer therapies and prevention strategies.


During this congress, four posters from four different University Medical Centres were presented on studies performed with PamGene technology. The studies cover different types of diseases and therefore prove the broad applicability of the PamGene technology.
Possible targets for future treatment of metastatic malignant melanoma found
Metastatic melanoma is an aggressive form of cancer that responds poorly to conventional chemotherapy. With this study, Andliena Tahiri from Akerhus University hospital in Oslo, Norway, e.a. aimed to obtain information about the tyrosine kinase activity in metastatic malignant melanoma before and after treatment with kinase inhibitors. The results of measurements with the PamGene technology show that kinase activity is generally higher in melanoma samples compared to normal skin. The use of kinase inhibitors caused inhibiton of the corresponding signalling pathways. The researchers conclude that kinases involved in the MAPK pathway may serve as important targets for the future treatment of metastatic malignant melanoma.
Download the poster
Crizotinib possible treatment in late stage uveal melanoma
Uveal melanoma (UM) is an intraocular neoplasm with an annual incidence of seven per million. In cells derived from UM metastasis, cells apparently use different pathways to survive. In order to identify treatment targets for metastasis patients, Mark de Lange from LUMC, Leiden, Netherlands, e.a. set out to identify that pathway. They tested the efficacy of c-Met inhibitor Crizotinib and investigated primary and downstream targets to delineate the role of c-Met signalling in UM progression. The data support the use of Crizotinib in late stage UM and reveal altered c-Met signalling in uveal melanoma progression.
PamGene technology provides a plausible model system to detect ALK activity
Mutated forms of the oncogene ALK have been shown to drive development of neuroblastoma, the most common malignant brain tumour in childhood. Schulte, from the Department of Pediatric Hematology and Oncology, University Children's Hospital Essen e.a. established that the PamChip ® peptide microarray can detect ALK activity of recombinant kinases, cell lysates and tumour lysates. Based on results with model systems, this method shows a possibility to identify tumours that express elevated ALK activity and to study response of this class to ALK inhibitors.
Download the poster 
Array-based tumour kinase activity profiling may lead to fingerprints for personalized treatment 
Mariette Labots e.a. from the VU University Medical Center, Amsterdam, Netherlands evaluated the PamGene array for the measurement of kinase activity in tumour tissue and cancer cell lines under various experimental conditions. They concluded that kinase activity profiles in lysates from cancer cell lines and patient-derived tumour tissue can be reproduced with a tyrosine kinase peptide substrate array. In addition, TKIs show differential ATP-dependent inhibition profiles on this array. Taken together, they expect that array-based tumour kinase activity profiling may lead to specific TKI-phosphorylation fingerprints for personalized treatment.
Read all abstracts here